Following a difficult year that saw Ixchiq’s license suspended in the US, Valneva is pinning hopes on upcoming pipeline ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management ...

Add Yahoo as a preferred source to see more of our stories on Google. Valneva and the Serum Institute of India (SII) have ended a license agreement for chikungunya vaccine supply in Asia after only a ...

Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its ...

Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and commercial attractiveness Saint Herblain (France), January 19 ...

If you are wondering whether Valneva is priced attractively right now, it helps to step back and look at what the recent ...

Valneva (VALN) and the world’s largest vaccine maker, Serum Institute of India, announced on Wednesday that they have mutually agreed to discontinue their licensing agreement for the former’s ...

The Company is also withdrawing the Investigational New Drug Application for Ixchiq after it was placed on clinical hold by the Agency due to a newly reported serious adverse event outside of the US.

Valneva SE (NASDAQ: VALN) on Monday said it has decided to voluntarily withdraw the biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, ...

Valneva (VALN) expects total revenue of €155M–€170M in 2026, including product sales of €145M–€160M. The lower product sales outlook versus 2025 reflects continued growth in core commercial brands, ...